MedTrace Logo

A Study of ADX-102 in Subjects With Allergic Conjunctivitis

NCT03012165 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 154

Last updated 2023-01-09

Study results available
· View outcomes & findings →

Summary

A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Phase 2b Evaluation of the Onset and Duration of ADX-102 Ophthalmic Drops (0.5% and 0.1%) Compared to Vehicle of ADX-102 Ophthalmic Drops in the Conjunctival Allergen Challenge (Ora-CAC®) Model of Acute Allergic Conjunctivitis.

Conditions

  • Conjunctivitis, Allergic

Interventions

DRUG

ADX-102 Ophthalmic Drops (0.5%)

ADX-102 Ophthalmic Drops (0.5%) administered twice in two weeks.

DRUG

ADX-102 Ophthalmic Drops (0.1%)

ADX-102 Ophthalmic Drops (0.1%) administered twice in two weeks.

DRUG

Vehicle of ADX-102 Ophthalmic Drops

Vehicle of ADX-102 Ophthalmic Drops administered twice in two weeks.

Sponsors & Collaborators

  • ORA, Inc.

    collaborator INDUSTRY

  • Aldeyra Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2017-05-31
Completion
2017-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03012165 on ClinicalTrials.gov